Can a drug duo save insulin-making cells in type 1 diabetes?

NCT ID NCT05742243

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining two safe immune therapies—abatacept injections and nasal insulin—can help preserve the pancreas's ability to make insulin in people recently diagnosed with type 1 diabetes. The goal is to make blood sugar control easier and reduce the need for injected insulin. The trial involved 68 participants aged 6 to 21, who received treatment for 48 weeks and were followed for another 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glucose intolerance hypoglycemia type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Perth Children's Hospital

    Nedlands, Western Australia, 6009, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, 4101, Australia

  • The Children's Hospital at Westmead

    Westmead, New South Wales, 2145, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, 3052, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

  • Women's and Children's Hospital

    North Adelaide, South Australia, 5006, Australia